151751-Najiba-Chargi

212 CHAPTER 11 REFERENCES 1. Grégoire V, Lefebvre J-L, Licitra L, Felip E. Squamous cell carcinoma of the head and neck: EHNS–ESMO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol . 2010;21:v184-v186. doi:10.1093/annonc/mdq185 2. Szturz P, Wouters K, Kiyota N, et al. Low- Dose vs. High-Dose Cisplatin: Lessons Learned From 59 Chemoradiotherapy Trials in Head and Neck Cancer. Front Oncol . 2019;9. doi:10.3389/fonc.2019.00086 3. Pignon J-P, Maître A le, Maillard E, Bourhis J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients. Ra- diother Oncol . 2009;92(1):4-14. doi:10.1016/j. radonc.2009.04.014 4. Strojan P, Vermorken JB, Beitler JJ, et al. Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: A systematic review. Eisele DW, ed. Head Neck . 2016;38(S1):E2151-E2158. doi:10.1002/hed.24026 5. Spreafico A, Huang SH, Xu W, et al. Impact of cisplatin dose intensity on human pap- illomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma. Eur J Cancer . 2016;67:174-182. doi:10.1016/j.ejca.2016.08.013 6. Al-Mamgani A, de Ridder M, Navran A, Klop WM, de Boer JP, Tesselaar ME. The impact of cumulative dose of cisplatin on outcome of patients with head and neck squamous cell carcinoma. Eur Arch Oto-Rhino-Laryngolo- gy . 2017;274(10):3757-3765. doi:10.1007/ s00405-017-4687-4 7. Ang K, Zhang Q, Wheeler RH, et al. A phase III trial (RTOG 0129) of two radiation-cis - platin regimens for head and neck carci- nomas (HNC): Impact of radiation and cis - platin intensity on outcome. J Clin Oncol . 2010;28(15_suppl):5507-5507. doi:10.1200/ jco.2010.28.15_suppl.5507 8. Forastiere AA, Zhang Q, Weber RS, et al. Long-Term Results of RTOG 91-11: A Comparison of Three Nonsurgical Treat- ment Strategies to Preserve the Larynx in Patients With Locally Advanced Larynx Cancer. J Clin Oncol . 2013;31(7):845-852. doi:10.1200/JCO.2012.43.6097 9. Wendrich AW, Swartz JE, Bril SI, et al. Low skeletal muscle mass is a predictive factor for chemotherapy dose-limiting toxicity in patients with locally advanced head and neck cancer. Oral Oncol . 2017;71:26-33. doi:10.1016/j.oraloncology.2017.05.012 10. Rier HN, Jager A, Sleijfer S, Maier AB, Levin M. The Prevalence and Prognostic Value of Low Muscle Mass in Cancer Patients: A Review of the Literature. Oncologist . 2016;21(11):1396-1409. doi:10.1634/theon - cologist.2016-0066 11. Hopkins JJ, Sawyer MB. Interactions of lean soft-tissue and chemotherapy toxicities in patients receiving anti-cancer treatments. Cancer Chemother Pharmacol . 2018;82(1):1- 29. doi:10.1007/s00280-018-3614-8 12. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on defini- tion and diagnosis: Report of the Europe- an Working Group on Sarcopenia in Older People. Age Ageing . 2010;39(4):412-423. doi:10.1093/ageing/afq034 13. Bril SI, Pezier TF, Tijink BM, Janssen LM, Braunius WW, de Bree R. Preoperative low skeletal muscle mass as a risk factor for pharyngocutaneous fistula and decreased overall survival in patients undergoing total laryngectomy. Head Neck . 2019;41(6):1745- 1755. doi:10.1002/hed.25638 14. Stone L, Olson B, Mowery A, et al. Associa - tion Between Sarcopenia and Mortality in Patients Undergoing Surgical Excision of Head and Neck Cancer. JAMA Otolaryngol Neck Surg . 2019;145(7):647. doi:10.1001/ jamaoto.2019.1185